吉甘醇对高尿血症的治疗效果和机制
Yuanfan Wu1, Xia Sun2, Yuhan Jia3
1Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Frontiers in endocrinology
|August 13, 2025
概括
吉根托尔通过减少尿酸的产生和增加排泄来有效地治疗高尿血 (HUA). 它还抑制了NLRP3炎症通路的激活,为HUA提供了一种新的治疗方法.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 超尿血症 (HUA) 是一种代谢状况,其特征是尿酸 (UA) 水平升高.
- NLRP3炎症酶途径在HUA病变发生过程中发挥作用.
- 了解HUA的机制对于开发有效治疗方法至关重要.
研究的目的:
- 为了评估巨醇对高尿血症 (HUA) 的治疗效果.
- 调查基因机制,通过巨醇对HUA产生影响.
- 评估巨醇对尿酸水平,功能标志物和炎症通路的影响.
主要方法:
- 已建立的HUA小鼠模型使用氧酸盐测量.
- 开发了HUA诱导的HK-2和AML12细胞模型,由腺和丁氧化酶 (XOD) 诱导.
- 使用ELISA测量尿酸 (UA),肌素 (CRE) 和血液尿素 (BUN) 的血清和尿液水平;评估XOD活性和NLRP3炎症组分 (例如IL-1β).
主要成果:
- HUA模型显示了血清UA,CRE和BUN的增加,尿道分泌量减少.
- 吉冈醇治疗逆转了这些影响,降低了血清标记物,增加了UA,CRE和BUN的尿路分泌.
- 吉甘醇显著降低了NLRP3和IL-1β水平,表明抑制了NLRP3炎症途径.
结论:
- 吉甘醇在治疗高尿血症 (HUA) 中表现出显著的治疗疗效.
- 它的机制涉及抑制丁氧化酶 (XOD) 活性,以减少UA的产生.
- 此外,Gigantol通过调节UA载体来增强UA的分泌,并抑制NLRP3炎症酶激活.
相关概念视频
01:16Antihypertensive Drugs: Action of Diuretics
871
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
871
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
01:17Oral Hypoglycemic Agents: Sulfonylureas
329
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
329
01:24Phase II Reactions: Glucuronidation
778
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
778
01:26Heart Failure Drugs: Inotropic Agents
722
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
722
01:06Oral Hypoglycemic Agents: Glinides
261
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
261